Methylergometrine (Maleate) - Drug Monograph

Primary Characteristics

It is of Synthetic origin and belongs to Ergot Alkaloid.

It belongs to Alpha adrenergic agonist pharmacological group on the basis of mechanism of action and also classified in Ergot Alkaloid pharmacological group. It is also classified under Psychotherapeutic Drugs .

Molecular Weight: 455.5 · pK_a: 6.65 · Solubility in Water: 1 in 100 · Solubility in Alcohol: 1 in 175 · Non-proprietary name: Methylergometrine (Maleate).

Molecular structure of Methylergometrine (Maleate)

Pharmacokinetics

Absorption: Methylergometrine (Maleate) has an oral bioavailability is 95.5% (±4.5%), pre-systemic (first-pass) metabolism accounts for 35% (±5%).

Distribution: Methylergometrine (Maleate) has a volume of distribution is 0.33-0.67 l/kg. plasma protein binding is 35 %.

Elimination: it is metabolised via Hepatic, plasma half-life is 2-3 hr, renal excretion is 3%.

Indications

Methylergometrine (Maleate) is primarily indicated in conditions like Postabrortal haemorrhage, Postpartum haemorrhage, Postpartuum haemorrhage, Uterine bleeding, Uterine subinvolution.

Methylergometrine (Maleate) is also indicated for secondary conditions like Uterine atonia.

Contraindications

Methylergometrine (Maleate) is contraindicated in conditions like Abortion, Heart disease, Peripheral obliterative vascular disease, Arteriovenous shunt, Labor augmentation, Pregnancy-induced hypertension.

Dosage

Methylergometrine (Maleate)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
200 ug	200 ug	—	IM,Slow IV	For prevention of postpartum haemorrhage 5 doses are given.
187.5 mg	187.5 mg	Every 8h	Oral
Paediatric Dosage (20kg)
0 – 0	—	—		Not recommended for this age group
Neonatal Dosage (3kg)
0 – 0	—	—		Not recommended in this age group

Drug Interactions

2 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Methylergometrine (Maleate) in overdosage may give rise to further complications which include Vascular complications , Ischemia, Gangrene , Cold extremities.

Methylergometrine (Maleate) produces potentially life-threatening effects which include Coma, Seizures , Nausea, Vomiting, Hypertension, Hypotension, Diarrhea. Careful monitoring is needed with proper medical management.

The signs and symptoms that are produced after acute overdosage of Methylergometrine (Maleate) are Nausea, Vomiting, Seizures, Angina , Confusion , Unconsciousness, Palpitations , Dizziness, Hypertension, Gangrene , Dyspnea, Vasoconstriction of the extremities.

Methylergometrine (Maleate) is known to cause more or less tolerable side effects which are usually transient. These include Abdominal pain, Angina, Chest pain, Headache, Nausea, Palpitation, Shortening of breath, Tinnitus, VertigoX, Vomiting .

Warnings / Precautions

Methylergometrine should not be used for the induction of labor or during the first stage of labor. Its use should be avoided in patients with eclampsia. IV injection should be given slowly. The drug should be administered under careful obstetric supervision to shorten the third stage of the labor after the delivery of the anterior shoulder of the fetus.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Caps

0.125 mg

Inj

0.2 mg 0.2 mg/ml

Tabs

0.125 mg

Multi-Ingredient Combinations

Inj

0.2 mg 0.2 mg/ml

Storage Conditions

Methylergometrine (Maleate) should be stored Tab, IV Inj, IM Inj.

Drug Classification

1.22.1.1 — Oxytocics

Manufacturers

Manufacturers of Methylergometrine (Maleate) in Pakistan:

Bonn Novartis Shaigan